Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes

Area of Science:

• Immunology
• Endocrinology
• Pharmacology

Background:

• Type 1 diabetes (T1D) mouse models show treatment success, but translation to human T1D is limited.
• Treatments are often tested at diagnosis, not reflecting advanced human disease states.
• Existing therapies for T1D require further development for broader clinical application.

Purpose of the Study:

• To evaluate a novel combination therapy for reversing hyperglycemia in nonobese diabetic (NOD) mice with new-onset and established type 1 diabetes.
• To assess the efficacy of combining antithymocyte globulin (ATG), G-CSF, DPP-4 inhibitor (DPP-4i), and proton pump inhibitor (PPI).
• To investigate the immunomodulatory mechanisms underlying the therapeutic effects.

Main Methods:

• Treatment of NOD mice with new-onset and established T1D using combinations of four drugs: ATG, G-CSF, DPP-4i, and PPI.
• Assessment of disease remission rates and blood glucose levels.
• Immunological analysis focusing on CD4+ T cells, CD8+ T cells, and natural killer cells.

Main Results:

• Combination therapy induced remission in 83% of new-onset and 50% of established T1D NOD mice.
• Remission was achieved regardless of initial blood glucose levels.
• Therapy enhanced immunoregulation, altering T cell and NK cell populations, and allowed for reduced drug doses with retained efficacy.

Conclusions:

• A four-drug combination therapy demonstrates significant efficacy in reversing both new-onset and established T1D in a relevant mouse model.
• The combination therapy promotes immune system modulation, offering a potential new avenue for T1D treatment.
• This approach, using approved drugs at reduced doses, shows promise for translational application in human T1D therapy.